Drug details

Blenrep (belantamab mafodotin-blmf for injection)

type of Anti-BCMA Antibodies

Blenrep (belantamab mafodotin-blmf) is a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate used to treat adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

The drug is often used to treat Multiple myeloma .

This drug may have the following side effects:

• nausea,
• diarrhea,
• fever,
• blurred vision,
• joint pain,
• back pain,
• fatigue,
• keratopathy (corneal epithelium changes on eye exam),
• decreased visual acuity,
• infusion-related reactions,
• decreased platelets,
• decreased lymphocytes,
• decreased hemoglobin,
• decreased neutrophils,
• increased creatinine,
• increased gamma-glutamyl transferase,
• dry eyes, constipation,
• decreased appetite, and
• upper respiratory tract infection

The following drugs are related to Blenrep, either as a replacement or used together:

• Abecma (idecabtagene vicleucel suspension)
• Adriamycin PFS (doxorubicin hydrochloride)
• Treanda (bendamustine hydrochloride injection)
• Carvykti (ciltacabtagene autoleucel for iv injection)
• Cytoxan (cyclophosphamide)
• Doxil (doxorubicin hcl liposome injection)
• Tecvayli (teclistamab-cqyv injection)
• Vincristine Sulfate Injection (vincristine sulfate)